靶向CD70的同种异体CAR-T细胞疗法治疗晚期透明细胞肾细胞癌
本文报告靶向CD70的同种异体CAR-T产品CTX130在临床前显示增殖与细胞毒性良好并完全消退肾细胞癌异种移植瘤,在16例复发/难治性透明细胞肾细胞癌患者的I期多中心首次人体试验中未出现剂量限制性毒性,疾病控制率81.3%,1例患者持续完全缓解3年,并报告下一代产品CTX131的临床前改进。
要点
- CTX130在临床前显示良好增殖与细胞毒性,并使肾细胞癌异种移植瘤完全消退。
- 16例复发/难治性透明细胞肾细胞癌患者接受CTX130,未出现剂量限制性毒性,疾病控制率81.3%。
- 1例患者持续完全缓解3年,下一代CTX131在临床前显示扩增与疗效改善。
核心结论
- 这些数据为靶向CD70的同种异体CAR-T细胞治疗透明细胞肾细胞癌及其他CD70阳性恶性肿瘤提供了概念验证。
研究设计与样本
- CTX130为靶向CD70的同种异体CAR-T产品,开发用于晚期或难治性透明细胞肾细胞癌。
- 报告16例复发/难治性透明细胞肾细胞癌患者接受CTX130的I期多中心首次人体临床试验结果。
- 临床前研究评估CTX130的增殖、细胞毒性及对肾细胞癌异种移植瘤的作用,并评估下一代产品CTX131。
主要发现
- CTX130在临床前显示良好的增殖与细胞毒性特征,并使肾细胞癌异种移植瘤完全消退。
- 16例接受CTX130的患者中无人出现剂量限制性毒性,81.3%的患者达到疾病控制。
- 1例患者在3年时仍维持持续完全缓解。
- 下一代CAR-T构建体CTX131通过对CTX130的协同效力编辑,在临床前研究中显示扩增与疗效改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product, was developed for the treatment of advanced or refractory ccRCC. We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial. No patients encountered dose-limiting toxicity, and disease control was achieved in 81.3% of patients. One patient remains in a durable complete response at 3 years. Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. These data represent a proof of concept for the treatment of ccRCC and other CD70+ malignancies with CD70- targeted allogeneic CAR T cells. Significance: Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors.
引用
- Pal SK, Tran B, Haanen JBAG, et al. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov. 2024. PMID: 38583184. doi:10.1158/2159-8290.CD-24-0102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。